logo
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX

Yahoo21-03-2025

RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other ophthalmic disorders, today announced that a presentation featuring the LYNX-1 Phase 3 study of Phentolamine Ophthalmic Solution 0.75% in patients with dim light disturbances will be delivered this week at World Cornea Congress IX, taking place March 20-22, 2025 in Washington, D.C.
Key highlights from the presentation
As previously reported, the LYNX-1 Phase 3 study met its primary endpoint, with a statistically significant greater percentage of Phentolamine Ophthalmic Solution 0.75%-treated participants gaining 15 or more letters of mesopic low contrast distance visual acuity (mLCVA) at Day 8, compared to placebo (13% vs. 3%; p<0.05).
The effect of Phentolamine Ophthalmic Solution 0.75% increased at Day 15, with 21% of participants gaining 15 or more letters of mLCVA compared to 3% of participants given the placebo (p<0.01).
Patient reported outcomes for glare, halos, and starbursts were significantly lower for the Phentolamine Ophthalmic Solution 0.75% group compared to placebo at Day 15 (p<0.01).
A subset analysis of post-LASIK participants demonstrated clinically meaningful results at Day 8, with 29% of Phentolamine Ophthalmic Solution 0.75% participants gaining 15 or more letters of mLCVA compared to 9% of participants given the placebo.
The effect of Phentolamine Ophthalmic Solution 0.75% was sustained at Day 15 in post-LASIK participants, with 21% of participants gaining 15 or more letters of mLCVA compared to 0% of participants given the placebo.
The positive LYNX-1 Phase 3 data support the rational of the ongoing Phase 3 LYNX-2 trial of Phentolamine Ophthalmic Solution 0.75% for keratorefractive patients with reduced mLCVA with photic phenomena. LYNX-2 is fully enrolled, with topline results expected mid 2025.
The full abstract can be accessed at the World Cornea Congress IX website here.
'We are pleased to present the results from the LYNX-1 Phase 3 trial of Phentolamine Ophthalmic Solution 0.75%, including a subset analysis highlighting results from participants who underwent some form of keratorefractive surgery, including LASIK,' said Jay Pepose, M.D., PhD., Chief Medical Advisor at Opus Genetics. 'Some patients who underwent keratorefractive surgery have experienced debilitating reduced mesopic vision and are more likely to be involved in motor vehicle collisions. Phentolamine Ophthalmic Solution 0.75% has the potential to be the first treatment for keratorefractive patients suffering from these debilitating symptoms.'
Presentation details
Title:
Randomized, Placebo-Controlled, Double-Masked Phase 3 Studies of Phentolamine Solution in Keratorefractive Patients with Dim Light Disturbances and Decreased Mesopic Vision
Presenter:
Jay Pepose, M.D., Ph.D. (Chief Medical Advisor, Opus Genetics)
Session:
Paper Session 2
Date/time:
Friday, March 21, 2025 at 2:10 – 2:16 PM ET
Location:
Rock Creek C, Ballroom Level, Westin Washington DC Downtown
About Opus Genetics
Opus Genetics is a clinical-stage ophthalmic biotechnology company developing gene therapies to treat patients with inherited retinal diseases (IRDs) and other treatments for ophthalmic disorders. The pipeline includes adeno-associated virus (AAV)-based investigational gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. Our most advanced investigational gene therapy program is designed to address mutations in the LCA5 gene, which encodes the lebercilin protein and is currently being evaluated in a Phase 1/2 open-label, dose-escalation trial, with encouraging early data. BEST1 investigational gene therapy is designed to address mutations in the BEST1 gene, which is associated with retinal degeneration; we expect that a Phase 1/2 study will be initiated in 2025. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist being investigated to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1, being investigated to slow the progression of non-proliferative diabetic retinopathy. Phentolamine Ophthalmic Solution 0.75% is currently being evaluated in Phase 3 trials for treatment of presbyopia and reduced dim (mesopic) light low contrast vision following keratorefractive surgery. We have reached agreement with the FDA on a SPA for a Phase 3 trial to evaluate oral APX3330 for the treatment of DR. For more information, please visit www.opusgtx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements concerning data from and future enrollment for our clinical trials and our pipeline of additional indications.
These forward-looking statements relate to us, our business prospects and our results of operations and are subject to certain risks and uncertainties posed by many factors and events that could cause our actual business, prospects and results of operations to differ materially from those anticipated by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those described under the heading 'Risk Factors' included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 and in our other filings with the U.S. Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. In some cases, you can identify forward-looking statements by the following words: 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'aim,' 'may,' 'ongoing,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. We undertake no obligation to revise any forward-looking statements in order to reflect events or circumstances that might subsequently arise.
These forward-looking statements are based upon our current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation:
Our ability to successfully integrate the business of former Opus Genetics Inc. and manage our expanded combined product pipeline;
Our ability to develop and obtain regulatory approval for newly acquired gene therapies to treat inherited retinal diseases;
Our ability to obtain and maintain orphan drug designation or rare pediatric disease designation for our current and future product candidates;
The success and timing of regulatory submissions and pre-clinical and clinical trials, including enrollment and data readouts;
Regulatory requirements or developments;
Changes to or unanticipated events in connection with clinical trial designs and regulatory pathways;
Delays or difficulties in the enrollment of patients in clinical trials;
Substantial competition, including from generic versions of our product candidates;
Rapid technological change;
Our development of sales and marketing infrastructure;
Future revenue losses and profitability;
Changes in capital resource requirements;
Risks related to our inability to obtain sufficient additional capital to continue to advance our product candidates and our preclinical programs;
Domestic and worldwide legislative, regulatory, political and economic developments;
Our dependency on key personnel;
Changes in market opportunities and acceptance;
Reliance on third parties to conduct our clinical trials and supply and manufacture drug supplies;
Future, potential product liability and securities litigation;
System failures, unplanned events, or cyber incidents;
The substantial number of shares subject to potential issuance associated with our equity line of credit arrangement;
Risks that our licensing or partnership arrangements may not facilitate the commercialization or market acceptance of our product candidates;
Future fluctuations in the market price of our common stock;
Actions by activist stockholders;
The success and timing of commercialization of any of our product candidates;
Obtaining and maintaining our intellectual property rights; and
The success of mergers and acquisitions.
The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission that advise interested parties of the risks and factors that may affect our business. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Contacts
Corporate
Investor Relations
Nirav JhaveriCFOir@opusgtx.com
Corey Davis, Ph.D.LifeSci Advisorscdavis@lifesciadvisors.comSign in to access your portfolio

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Alabama Dept. of Public Health reports no measles detected after investigation
Alabama Dept. of Public Health reports no measles detected after investigation

Yahoo

time24 minutes ago

  • Yahoo

Alabama Dept. of Public Health reports no measles detected after investigation

COLUMBUS, Ga. () — The Alabama Department of Public Health (ADPH) has determined that the unvaccinated person being investigated in Lee County, Alabama, does not have measles. The ADPH says that due to the extremely contagious risk of measles in unvaccinated people, they regularly launch investigations on suspected cases to ensure that vulnerable and potentially exposed people are informed and protected. 'This investigation began on Saturday afternoon. I appreciate the quick response of the ADPH on call team to ensure that all the response elements were in place, in order to protect Alabama.' ADPH Chief Medical Officer, Dr. Karen Landers said. 'While ADPH has determined that this is not a case of measles, I urge all Alabamians to be vigilant in ensuring that eligible persons are up to date on the MMR vaccine. The MMR vaccine is safe and effective. High rates of MMR vaccine in our state will protect our children, our families, and our citizens from this severe and deadly disease.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

SmartStop Prices Canadian Maple Bond Offering
SmartStop Prices Canadian Maple Bond Offering

Yahoo

time26 minutes ago

  • Yahoo

SmartStop Prices Canadian Maple Bond Offering

LADERA RANCH, Calif., June 11, 2025--(BUSINESS WIRE)--SmartStop Self Storage REIT, Inc. ("SmartStop") (NYSE: SMA), an internally managed real estate investment trust and a premier owner and operator of self-storage facilities in the United States and Canada, announced the pricing of a Canadian Maple Bond offering. SmartStop's affiliated operating partnership, SmartStop OP, L.P., will issue CAD $500 million of series A senior unsecured notes due June 16, 2028 (the "Notes"). The Notes bear interest at a rate of approximately 3.91% per annum, payable in cash in equal semi-annual installments, commencing on December 16, 2025. The effective interest rate on the indentures after accounting for an interest rate hedge is approximately 3.85%. The Notes are rated BBB (Stable) by Morningstar DBRS. SmartStop intends to use the net proceeds from the offering to repay outstanding higher interest rate indebtedness, fund acquisitions and for general corporate purposes. The closing of the offering is expected to occur on June 16, 2025, subject to the satisfaction of customary closing conditions. The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities laws in the United States and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws. The Notes were offered exclusively to persons resident in a Canadian province through a syndicate of agents on a private placement basis. The Notes will not be sold to investors outside of Canada. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. About SmartStop Self Storage REIT, Inc. (SmartStop): SmartStop Self Storage REIT, Inc. ("SmartStop") (NYSE: SMA) is a self-managed REIT with a fully integrated operations team of approximately 590 self-storage professionals focused on growing the SmartStop® Self Storage brand. SmartStop, through its indirect subsidiary SmartStop REIT Advisors, LLC, also sponsors other self-storage programs. As of June 11, 2025, SmartStop has an owned or managed portfolio of 222 operating properties in 23 states, the District of Columbia, and Canada, comprising approximately 158,900 units and 17.9 million rentable square feet. SmartStop and its affiliates own or manage 42 operating self-storage properties in Canada, which total approximately 35,700 units and 3.6 million rentable square feet. View source version on Contacts David Corak Senior VP of Corporate Finance and StrategySmartStop Self Storage REIT,

SmartStop Prices Canadian Maple Bond Offering
SmartStop Prices Canadian Maple Bond Offering

Business Wire

time30 minutes ago

  • Business Wire

SmartStop Prices Canadian Maple Bond Offering

LADERA RANCH, Calif.--(BUSINESS WIRE)--SmartStop Self Storage REIT, Inc. ('SmartStop') (NYSE: SMA), an internally managed real estate investment trust and a premier owner and operator of self-storage facilities in the United States and Canada, announced the pricing of a Canadian Maple Bond offering. SmartStop's affiliated operating partnership, SmartStop OP, L.P., will issue CAD $500 million of series A senior unsecured notes due June 16, 2028 (the 'Notes'). The Notes bear interest at a rate of approximately 3.91% per annum, payable in cash in equal semi-annual installments, commencing on December 16, 2025. The effective interest rate on the indentures after accounting for an interest rate hedge is approximately 3.85%. The Notes are rated BBB (Stable) by Morningstar DBRS. SmartStop intends to use the net proceeds from the offering to repay outstanding higher interest rate indebtedness, fund acquisitions and for general corporate purposes. The closing of the offering is expected to occur on June 16, 2025, subject to the satisfaction of customary closing conditions. The Notes will not be registered under the Securities Act of 1933, as amended (the 'Securities Act'), or any state securities laws in the United States and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements under the Securities Act and applicable state securities laws. The Notes were offered exclusively to persons resident in a Canadian province through a syndicate of agents on a private placement basis. The Notes will not be sold to investors outside of Canada. This news release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. About SmartStop Self Storage REIT, Inc. (SmartStop): SmartStop Self Storage REIT, Inc. ('SmartStop') (NYSE: SMA) is a self-managed REIT with a fully integrated operations team of approximately 590 self-storage professionals focused on growing the SmartStop® Self Storage brand. SmartStop, through its indirect subsidiary SmartStop REIT Advisors, LLC, also sponsors other self-storage programs. As of June 11, 2025, SmartStop has an owned or managed portfolio of 222 operating properties in 23 states, the District of Columbia, and Canada, comprising approximately 158,900 units and 17.9 million rentable square feet. SmartStop and its affiliates own or manage 42 operating self-storage properties in Canada, which total approximately 35,700 units and 3.6 million rentable square feet.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store